Shares of Suven Life Sciences were up 7% at Rs 299 after the company said it has secured three product patents for its new chemical entities in Canada, Japan and Korea.
The drugs are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, the company today said in a release to the stock exchanges.
With these new patents, Suven has a total of eighteen (18) granted patents from Canada, sixteen (16) granted patents from Japan, and sixteen (16) product patents from Korea, the release added.
The stock opened at Rs 278 and touched a high of Rs 304. Until 12:45PM, over 4.7 million shares were traded on both the stock exchanges.
